Surmodics (NASDAQ:SRDX) Cut to D at TheStreet

TheStreet downgraded shares of Surmodics (NASDAQ:SRDX – Get Rating) from a c rating to a d rating in a research report report published on Friday morning, TheStreetRatingsTable reports.

Several other brokerages also recently commented on SRDX. StockNews.com started coverage on shares of Surmodics in a report on Thursday, March 31st. They issued a hold rating on the stock. Needham & Company LLC cut their price objective on Surmodics from $70.00 to $58.00 and set a buy rating for the company in a research report on Friday, February 4th.

SRDX opened at $37.95 on Friday. The business’s 50-day moving average is $42.65. Surmodics has a 52-week low of $36.24 and a 52-week high of $62.27.

Surmodics (NASDAQ:SRDX – Get Rating) last announced its earnings results on Wednesday, April 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.10. Surmodics had a negative return on equity of 6.22% and a negative net margin of 10.80%. During the same quarter in the previous year, the company earned $0.62 earnings per share. On average, research analysts expect that Surmodics will post -1.15 earnings per share for the current year.

In other Surmodics news, CEO Gary R. Maharaj sold 4,000 shares of the stock in a transaction on Friday, April 1st. The shares were sold at an average price of $44.99, for a total value of $179,960.00. Following the completion of the sale, the chief executive officer now directly owns 155,041 shares of the company’s stock, valued at approximately $6,975,294.59. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.70% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Sphinx Trading LP bought a new stake in shares of Surmodics during the fourth quarter valued at approximately $39,000. Cubist Systematic Strategies LLC bought a new stake in Surmodics in the 4th quarter valued at $53,000. Marshall Wace LLP acquired a new position in shares of Surmodics in the 4th quarter valued at $83,000. Captrust Financial Advisors lifted its holdings in shares of Surmodics by 230.0% during the 3rd quarter. Captrust Financial Advisors now owns 1,828 shares of the company’s stock worth $102,000 after acquiring an additional 1,274 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in Surmodics in the fourth quarter worth about $144,000. 94.40% of the stock is currently owned by institutional investors.

About Surmodics (Get Rating)

Surmodics, Inc, together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).

Read More